Shanghai Wibson Biotechnology: difference between revisions
Diff·revision 43 → 44·06:50, 12 Sep 2025
Difference between revision 43 and revision 44 of Shanghai Wibson Biotechnology. 13 lines changed; the page grew by 1,614 bytes.
| Revision 43 — 20:10, 4 Sep 2025 CheckSumChase (talk) promote subsection to section 8,028 bytes +250 | Revision 44 — 06:50, 12 Sep 2025 EndotoxinEd (talk) expand §Operations and documentation practice 9,642 bytes +1,614 | ||
|---|---|---|---|
| 61 | The PeptidePedia tally records 915 self-reported submissions to July 2026. Recurring positive themes are responsiveness and delivery times; recurring complaints concern certificate depth.{{r|tally}} Self-selected sample; reception rather than quality.{{r|tally}} | 61 | The PeptidePedia tally records 915 self-reported submissions to July 2026. Recurring positive themes are responsiveness and delivery times; recurring complaints concern certificate depth.{{r|tally}} Self-selected sample; reception rather than quality.{{r|tally}} |
| 62 | 62 | ||
| + | 63 | === How this tally should be read === | |
| + | 64 | The reception figure above is a mean of self-reported submissions to PeptidePedia. It is '''weak evidence''' and is subject to three limitations that apply to every such figure on this wiki: | |
| + | 65 | ||
| + | 66 | * '''Self-selection.''' People who submit are not a sample of purchasers. Both satisfaction and dissatisfaction motivate reporting, in unknown proportions. | |
| + | 67 | * '''It measures reception, not quality.''' Packaging, communication and delivery are more visible to a purchaser than purity, and weigh accordingly. | |
| + | 68 | * '''It is not comparable across communities.''' Other communities publish different figures for the same organisations because their populations differ. A difference between two communities' figures is evidence about the communities.{{r|tally}} | |
| + | 69 | ||
| + | 70 | == Regulatory position and legal status == | |
| + | 71 | The organisation is a commercial entity registered in the People's Republic of China. Nothing in the available record indicates a manufacturing authorisation, marketing authorisation or pharmacopoeial registration in any jurisdiction, and none should be inferred from a registered business scope, which is a licensing fact and not a quality assurance.{{r|registry}} | |
| + | 72 | ||
| + | 73 | Material labelled [[Research use only|for research use only]] is outside the regulatory framework that governs medicines. Its identity, purity, sterility and [[Bacterial endotoxin test|endotoxin]] content are not assured by any regulator, and a [[Certificate of analysis|certificate of analysis]] issued by a supplier is a claim by that supplier rather than an independent finding.{{r|ruo,usp1503}} | |
| + | 74 | ||
| 63 | == References == | 75 | == References == |
| 64 | {{reflist}} | 76 | {{reflist}} |
| ⋮ | ⋮ | ||
| 81 | * [[Research use only]] | 93 | * [[Research use only]] |
| 82 | * [[Peptide supply chain]] | 94 | * [[Peptide supply chain]] |
| + | 95 | * [[Blind sampling]] | |
| 83 | 96 | ||
| 84 | {{DEFAULTSORT:Shanghai Wibson Biotechnology}} | 97 | {{DEFAULTSORT:Shanghai Wibson Biotechnology}} |